NEW YORK, Sept. 27 /PRNewswire-FirstCall/ -- Bristol-Myers Squibb (NYSE: BMY) announced today that Dr. Jeremy Levin has joined the company's Research and Development organization as senior vice president, External Science, Technology and Licensing. He will report to Dr. Elliott Sigal, chief scientific officer and president, Research and Development.
"I am delighted Jeremy has joined our R&D organization at this critical juncture for Bristol-Myers Squibb, as we look to further build our robust pipeline in areas of significant unmet medical need and to transform our pharmaceutical business for the future," said Dr. Sigal. "Jeremy's extensive global network in the pharmaceutical, biotechnology and venture industries will help ensure that we remain a leader in forging creative partnerships to advance the development of novel medicines."
Prior to joining Bristol-Myers Squibb, Dr. Levin served as Global Head of Business Development and Strategic Alliances at the Novartis Institutes of Biomedical Research. In that capacity, he and his team secured hundreds of collaborations in more than 20 countries since 2003. Prior to his tenure at Novartis, Dr. Levin held leadership positions in several biotechnology companies, including Physiome Sciences, Inc. and Cadus Pharmaceutical Corporation. He also was managing director of Perseus Capital LLC, a life sciences venture fund. He has served on the executive committees and boards of several public biosciences companies, as well as the Executive Committee of BIO and the boards of the Biotechnology Institute and the New York Biotechnology Association.
"I am excited about the tremendous opportunity at Bristol-Myers
Squibb," said Dr. Levin. "I am especially looking forward
'/>"/>
| SOURCE Bristol-Myers Squibb Copyright©2007 PR Newswire. All rights reserved |